Vaccines against human papillomaviruses - A major breakthrough in cancer prevention

Central European Journal of Public Health

Volumn 15, Issue 4, 2007, Pages 131-139

  Vonka, Vladimír ^a   Hamšíková, Eva ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Carcinoma of the cervix; HPV vaccines; Papillomavirus

Indexed keywords

EID: 37749012981     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: 10.21101/cejph.a3447     Document Type: Review

References (53)

1. Terris M, Wilson F, Smith H, Nelson JH Jr. Epidemiology of cancer of the cervix. V. The relationship of coitus to carcinoma of the cervix. Am J Public Health Nations Health. 1967 May;57(5):840-7.
2. Rotkin ID. Relation of adolescent coitus to cervical cancer risk. JAMA. 1962 Feb 17;179:486-91.
3. Kessler II. Human cervical cancer as a venereal disease. Cancer Res. 1976 Feb;36(2 pt 2):783-91.
4. Buckley JD, Harris RW, Doll R, Vessey MP, Williams PT. Case-control study of the husbands of women with dysplasia or carcinoma of the cervix uteri. Lancet. 1981 Nov 7;2(8254): 1010-5.
5. Vonka V, Kanka J, Roth Z. Herpes simplex type 2 virus and cervical neoplasia. Adv Cancer Res. 1987;48:149-91.
6. Schneweis KE. Serological relations of types 1 and 2 of Herpesvirus hominis to Herpesvirus simiae. Z Immun Exp Ther. 1962 Dec; 124:337-41. (In German.)
7. Nahmias AJ, Josey WE, Naib ZM, Luce CF, Guest BA. Antibodies to Herpesvirus hominis types 1 and 2 in humans. II. Women with cervical cancer. Am J Epidemiol. 1970 Jun;91(6):547-52.
8. Melnick JL, Adam E. Epidemiological approaches to determining whether herpesvirus is the etiological agent of cervical cancer. Prog Exp Tumor Res. 1978;21:49-69.
9. Rawls WE, Bacchetti S, Graham FL. Relation of Herpes simplex viruses to human malignancies. Curr Top Microbiol Immunol. 1977;77:71-95.
10. Janda Z, Kaňka J, Vonka V, Svoboda B. A study of herpes simplex type 2 antibody status in groups of patients with cervical neoplasia in Czechoslovakia. Int J Cancer. 1973 Nov 15;12(3):626-30.
11. Duff R, Rapp F. Properties of hamster embryo fibroblasts transformed in vitro after exposure to ultraviolet-irradiated herpes simplex virus type 2. J Virol. 1971 Oct;8(4):469-77.
12. Kutinová L, Vonka V, Brouček J. Increased oncogenicity and synthesis of herpesvirus antigens in hamster cells exposed to herpes simplex type-2 virus. J Natl Cancer Inst. 1973 Mar;50(3):759-66.
13. Palmer AE, London WT, Nahmias AJ, Naib ZM, Tunca J, Fuccillo DA, et al. A preliminary report on investigation of oncogenic potential of herpes simplex virus type 2 in Cebus monkeys. Cancer Res. 1976 Feb;36(2 pt 2):807-9.
14. Frenkel N, Roizman B, Cassai E, Nahmias A. A DNA fragment of Herpes simplex 2 and its transcription in human cervical cancer tissue. Proc Natl Acad Sci USA. 1972 Dec;69(12):3784-9.
15. Eglin RP, Sharp F, MacLean AB, Macnab JC, Clements JB, Wilkie NM. Detection of RNA complementary to herpes simplex virus DNA in human cervical squamous cell neoplasms. Cancer Res. 1981 Sep;41(9 Pt 1):3597-603.
16. Hollinshead AC, Lee O, Chretien PB, Tarpley JL, Rawls WE, Adam E. Antibodies to herpesvirus nonvirion antigens in squamous carcinomas. Science. 1973 Nov 16;182(113):713-5.
17. Aurelian L, Schumann B, Marcus RL, Davis HJ. Antibody to HSV-2 induced tumor specific antigens in serums from patients with cervical carcinoma. Science. 1973 Jul 13;181(95):161-4.
18. Anzai T, Dreesman GR, Courtney RJ, Adam E, Rawls WE, Benyesh-Melnick M. Antibody to herpes simplex virus type 2-induced nonstructural proteins in women with cervical cancer and in control groups. J Natl Cancer Inst. 1975 May;54(5):1051-9.
19. Vonka V. Causality in medicine: the case of tumours and viruses. Philos Trans R Soc Lond B Biol Sci. 2000 Dec 29;355(1404):1831-41.
20. zur Hausen H. Herpes simplex virus in human genital cancer. Int Rev Exp Pathol. 1983;25:307-26.
21. Galloway DA, McDougall JK. The oncogenic potential of herpes simplex viruses: evidence for a ,hit-and-run' mechanism. Nature. 1983 Mar 3;302(5903):21-4.
22. Matz B, Schlehofer JR, zur Hausen H. Identification of a gene function of herpes simplex virus type 1 essential for amplification of simian virus 40 DNA sequences in transformed hamster cells. Virology. 1984 Apr 30;134(2):328-37.
23. Vonka V, Kaňka J, Jelínek J, Šubrt I, Suchánek A, Havránková A, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int J Cancer. 1984 Jan 15;33(1):49-60.
24. Suchánková A, Hirsch I, Krčmář M, Vonka V. Determination of herpes simplex virus type-specific antibodies by solid-phase RIA on Helix pomatia lectin-purified antigens. J Infect Dis. 1984 Jun;149(6):964-72.
25. Vonka V, Kaňka J, Hirsch I, Závadová H, Krčmář M, Suchánková A, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer. 1984 Jan 15;33(1):61-6.
26. Adam E, Kaufman RH, Adler-Storthz K, Melnick JL, Dreesman GR. A prospective study of association of herpes simplex virus and human papillomavirus infection with cervical neoplasia in women exposed to diethylstilbestrol in utero. Int J Cancer. 1985 Jan 15;35(1): 19-26.
27. Lehtinen M, Hakama M, Aaran RK, Aromaa A, Knekt P, Leinikki P, et al. Herpes simplex virus type 2 infection and cervical cancer: a prospective study of 12 years of follow-up in Finland. Cancer Causes Control. 1992 Jul;3(4):333-8.
28. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983 Jun;80(12):3812-5.
29. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984 May;3(5):1151-7.
30. Vonka V, Hamšíková E, Kaňka J, Ludvíková V, Sapp M, Šmahel M. Prospective study on cervical neoplasia IV. Presence of HPV antibodies. Int J Cancer. 1999 Jan 29;80(3):365-8.
31. Tachezy R, Saláková M, Hamšíková E, Kaňka J, Havránková A, Vonka V. Prospective study on cervical neoplasia: presence of HPV DNA in cytological smears precedes the development of cervical neoplastic lesions. Sex Transm Infect. 2003 Jun;79(3):191-6.
32. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997 May 5;102(5A):3-8.
33. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006 Aug 21;24 Suppl 3:S52-S61.
34. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001 Jun 9;357(9271):1831-6.
35. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003 Feb 1;157(3):218-26. Erratum in: Am J Epidemiol. 2003 May 1;157(9):858.
36. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002 Jan;109(1):96-8.
37. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71.
38. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah K V, et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.
39. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 Aug 20;111(2):278-85.
40. Ferlay J, Bray F, Pisani P, Parkin DM, editors. Globocan 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press; 2004.
41. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991 Nov;185(1):251-7.
42. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol. 1993 Jan;67(1):315-22.
43. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus- like particles that are highly immunogenic. Proc Natl Acad Sci USA. 1992 Dec 15;89(24):12180-4.
44. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology. 1995 Jan 10;206(1):126-35.
45. Gall SA, et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. In: American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA, USA. Philadelphia: AACR; 2007. abstract no. 4900.
46. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006 Dec 4;95(11): 1459-66.
47. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006 Apr 15;367(9518):1247-55.
48. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of a human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007 Aug 15;298(7):743-53.
49. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov; 118(5):2135-45.
50. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al; HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavitus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007 Jun;40(6):564-71.
51. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer. 2004 Feb 20; 108(5): 766-72.
52. Tachezy R, Klozar J, Saláková M, Smith E, Turek L, Betka J, et al. HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic. Oral Dis. 2005 May;11(3):181-5.
53. Brandsma JL, Shlyankevich M, Zhang L, Slade MD, Goodwin EC, Peh W, et al. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol. 2004 Jan;78(1): 116-23.